BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10427884)

  • 1. [The prognostic factors in T1 superficial bladder carcinoma. Our experience].
    Moyano Calvo JL; Romero Díaz A; Ortíz Gamiz A; Sánchez Sánchez E; Blanco Palenciano E; Arribas Rodríguez JM; Castiñeiras Fernández J
    Arch Esp Urol; 1999 Jun; 52(5):465-70. PubMed ID: 10427884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
    Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
    Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of prognostic factors in superficial bladder tumors].
    Páez Borda A; Martín Osés E; de la Cal López M; Llorente Abarca C; Berenguer Sánchez A
    Arch Esp Urol; 1997 Mar; 50(2):121-6. PubMed ID: 9206936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors.
    Palou J; Rodríguez-Rubio F; Millán F; Algaba F; Rodríguez-Faba O; Huguet J; Villavicencio H
    Urology; 2009 Jun; 73(6):1313-7. PubMed ID: 19362341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
    Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
    Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
    Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
    J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.
    Kwak C; Ku JH; Park JY; Lee E; Lee SE; Lee C
    J Urol; 2004 Jan; 171(1):149-52. PubMed ID: 14665864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of random biopsies of healthy mucosa in superficial bladder tumor].
    Fernández Gómez JM; Rodríguez Martínez JJ; Escaf Barmadah S; Pérez García J; García J; Casasola Chamorro J
    Arch Esp Urol; 2000 Nov; 53(9):785-97. PubMed ID: 11196385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
    Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
    BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mid-term results of a program for the monitoring of superficial bladder tumors].
    Paez Borda A; Luján Galán M; Llanes González L; Gómez de Vicente JM; Berenguer Sánchez A
    Arch Esp Urol; 1999 Apr; 52(3):229-34; discussion 234-5. PubMed ID: 10371738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients.
    Orsola A; Trias I; Raventós CX; Español I; Cecchini L; Búcar S; Salinas D; Orsola I
    Eur Urol; 2005 Aug; 48(2):231-8; discussion 238. PubMed ID: 15963635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
    Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
    J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical prognostic factors in superficial cancer of the urinary bladder].
    Busto Catañón L; Sánchez Merino JM; Picallo Sánchez JA; Gelabert Mas A
    Arch Esp Urol; 2001 Mar; 54(2):131-8. PubMed ID: 11341116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.